Testing one versus two years of cancer maintenance treatment

Plain-English translation of NCT06580314 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing how long patients with advanced ovarian cancer should take a medication called after completing their initial chemotherapy. The study will compare taking this medication for one year versus two years, and will also look at whether adding another drug called improves results. The trial is for patients whose tumors have specific genetic changes (BRCA mutations or other DNA repair deficiencies) that make them good candidates for this type of treatment.

Doctors know that this medication helps prevent ovarian cancer from coming back after chemotherapy, but they don't yet know whether one year of treatment works just as well as two years. Finding the shortest effective treatment could help patients avoid unnecessary medication while still staying cancer-free.

Do you qualify?

You likely qualify if…

you have been newly diagnosed with stage III or IV ovarian, fallopian tube, or peritoneal cancer (high-grade serous, high-grade endometrioid, or carcinosarcoma types)
your tumor has a BRCA1 or BRCA2 gene mutation, or your tumor shows homologous recombination deficiency on genetic testing
you have already completed surgery for your cancer
you have completed at least 4 (preferably 6 or more) cycles of platinum-based chemotherapy and your cancer responded well or disappeared
you have not received a PARP inhibitor drug before
you are at least 18 years old with good overall health status

You likely don't qualify if…

you have already taken a PARP inhibitor drug like olaparib, niraparib, or rucaparib
you are pregnant or breastfeeding
your cancer has progressed or worsened after your first chemotherapy
you have a tumor type known to be mismatch repair deficient or microsatellite instability high (unless it also has a BRCA mutation)
more than 12 weeks have passed since your last chemotherapy dose

What participation looks like

If you join this trial, you will be randomly assigned to take the medication by mouth twice daily for either one year or two years. You may also receive an additional IV medication every three weeks for up to one year, depending on what your doctor recommends. Throughout the study, you will have regular blood tests and imaging scans (CT or MRI) to monitor how well the treatment is working and to check for any side effects. Most of your participation will happen during regular clinic visits over the course of one to two years.

AI-generated summary from trial data · Aug 13, 2026 · Not medical advice

Testing one versus two years of cancer maintenance treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations